Hydrazine compounds have been studied both as potential anticancer drugs and as cancer-causing agents. Early studies of hydrazines, including hydrazine sulfate, were conducted to determine whether these compounds could cause cancer in healthy laboratory animals.[1,2,3,4,5,6,7,8,9] Reviewed in [10,11] Substantial increases in tumor incidence were observed in most studies that used rats, mice, or hamsters.[1,2,3,4,5,7,8,9] Hydrazine administration was associated with increases in lung, liver, and breast tumors in rats,[2,5] increases in lung and liver tumors in mice,[1,2,3,4,8] and increases in liver tumors in hamsters.[7,9] In one study, hydrazine sulfate increased the incidence of lung tumors in both males and females of the mouse strain C3H, but reduced the incidence of breast adenocarcinomas in C3H females.
Animal studies of hydrazine sulfate as a treatment for cancer have investigated this compound as a single agent and in combination with established chemotherapy drugs.[12,13,14,15,16,17,18] In studies conducted in one laboratory, hydrazine sulfate alone was found to cause dose-dependent inhibition of tumor growth in rats bearing Walker 256 carcinosarcoma or Murphy-Sturm lymphosarcoma tumors and in mice bearing B-16 melanoma tumors.[12,13,14] Hydrazine sulfate alone had no effect on solid tumors formed from L-1210 leukemia cells in mice. In work performed in another laboratory, hydrazine sulfate alone inhibited the growth of FBCa bladder cancer tumors in one of two experiments in rats, but it had no effect on the growth of 13762NF mammary adenocarcinomas in rats. Findings from a third laboratory demonstrated that hydrazine sulfate alone had no effect on the growth of Dunning prostate cancer tumors in rats.
Treatment of recurrentparanasal sinus and nasal cavity cancer depends on where cancer is found in the paranasal sinuses and nasalcavity.
If cancer is in the maxillary sinus, treatment may include the following:
Surgery followed by radiation therapy.
Radiation therapy followed by surgery.
Chemotherapy as palliative therapy to relieve symptoms and improve the quality of life.
A clinical trial of chemotherapy.
If cancer is in the ethmoid sinus, treatment may include the following:
It is important to note that the best tumor responses to hydrazine sulfate as a single agent (i.e., tumor reductions of approximately 50% or more) were accompanied by substantial losses in animal body weight.[12,13,14] This finding appears to be inconsistent with the proposed use of hydrazine sulfate as an anticachexia agent.
In other experiments, hydrazine sulfate was combined with individual chemotherapy drugs (cyclophosphamide, mitomycin C, methotrexate, bleomycin, fluorouracil [5-FU], carmustine [BCNU], or neocarcinostatin) to treat Walker 256 carcinosarcoma tumors in rats and solid L-1210 leukemia tumors in mice.[13,14,15] For both tumor types, enhanced anticancer effects were observed. In the experiments with L-1210 tumors, cyclophosphamide and mitomycin C were more effective when combined with hydrazine sulfate than they were when used alone. As indicated previously, hydrazine sulfate alone had no effect against solid L-1210 tumors.
Addition of the drug clofibrate to the hydrazine sulfate plus chemotherapy drug combinations was reported to produce even greater antitumor effects. Clofibrate lowers blood lipid levels and has the potential to inhibit gluconeogenesis by limiting the availability of lipid breakdown products for the synthesis of glucose. Reviewed in  This three drug treatment regimen, however, was tested against only one type of tumor (Walker 256 carcinosarcomas in rats).